TITLE

Celebrating novel cancer drugs

AUTHOR(S)
Weiss, Robin A
PUB. DATE
August 2003
SOURCE
British Journal of Cancer;8/4/2003, Vol. 89 Issue 3, p425
SOURCE TYPE
Academic Journal
DOC. TYPE
Editorial
ABSTRACT
Editorial. Focuses on cancer drug development in Great Britain. Progress and development made in cancer drugs; Development of novel means of measuring efficacy, pharmacokinetics and pharmacodynamics of the drugs in action.
ACCESSION #
10389038

 

Related Articles

  • Recent Progress in the Development of Anticancer Agents. Sandor Eckhardt // Current Medicinal Chemistry - Anti-Cancer Agents;May2002, Vol. 2 Issue 3, p419 

    Cancer chemotherapy started with the discovery of the cytostatic effect of N-mustard and its derivatives more than five decades ago. This observation opened the way for the synthesis of various alkylating agents, antimetabolites and antimitotics expliciting antitumour activity against several...

  • An Integrated Disease/Pharmacokinetic/Pharmacodynamic Model Suggests Improved Interleukin-21 Regimens Validated Prospectively for Mouse Solid Cancers. Elishmereni, Moran; Kheifetz, Yuri; S√łndergaard, Henrik; Overgaard, Rune Viig; Agur, Zvia // PLoS Computational Biology;Sep2011, Vol. 7 Issue 9, p1 

    Interleukin (IL)-21 is an attractive antitumor agent with potent immunomodulatory functions. Yet thus far, the cytokine has yielded only partial responses in solid cancer patients, and conditions for beneficial IL-21 immunotherapy remain elusive. The current work aims to identify...

  • Soil DNA libraries for anticancer drug discovery. Pettit, Robin K. // Cancer Chemotherapy & Pharmacology;Jul2004, Vol. 54 Issue 1, p1 

    Soil has the largest population of microbes of any habitat, but only about 0.3% of soil microbes are cultivable with current techniques. Cultured soil microbes have been an incredibly productive source of drugs, for example the cancer chemotherapeutics doxorubicin hydrochloride, bleomycin,...

  • palliative care.  // Annals of Oncology;2016 Supplement, Vol. 27, pvi455 

    No abstract available.

  • Optimization of Breast Cancer Chemotherapy Regimens using a Pharmacokinetic/Pharmacodynamic Model-Based Design. Khaloozadeh, Hamid; Yazdani, Sahar; Kamyab, Manuchehr // Pharmaceutical Medicine - New Zealand;2009, Vol. 23 Issue 1, p11 

    This review presents a new optimal model-based regimen for cytotoxic chemotherapy. The main purpose of designing this improved regimen was to minimize the adverse effects of chemotherapy on healthy tissue whilst still destroying tumour cells. By considering the Gompertzian model for tumour and...

  • Population Pharmacokinetics of UCN-01. Baksh, Charlene A.; Edelman, Martin J.; Sausville, Edward A.; Figg, William D.; Hao Zhu; Bauer, Kenneth S. // Journal of Cancer Therapy;Dec2013, Vol. 4 Issue 10, p1513 

    UCN-01 (7-Hydroxystaurosporine) is an investigational anticancer agent that is currently being evaluated as targeted therapy in phase II clinical studies. The aims of this work were to describe the population pharmacokinetics of UCN-01 in patients with advanced solid tumors, and to identify...

  • Phase I and pharmacokinetic study of the novel redox-active agent, motexafin gadolinium, with concurrent radiation therapy in patients with locally advanced pancreatic or biliary cancers. Ramanathan, Ramesh K.; Fakih, Marwan; Mani, Sridhar; Deutsch, Melvin; Perez, Raymond P.; Ritter, Mark A.; Eiseman, Julie L.; Ivy, S. Percy; Trump, Donald L.; Belani, Chandra P.; Parise, Robert A.; Potter, Douglas M.; Egorin, Merrill J. // Cancer Chemotherapy & Pharmacology;Apr2006, Vol. 57 Issue 4, p465 

    Purpose: To determine the maximum tolerated dose and dose-limiting toxicity (DLT) of the novel anticancer agent, motexafin gadolinium (MGd), administered concurrently with radiation therapy (RT) in patients with locally advanced pancreatic or biliary tumors. The pharmacokinetics of...

  • daunorubicin hydrochloride.  // Davis's Drug Guide for Nurses, 10th edition;2007, p357 

    The article presents a nursing guide to daunorubicin hydrochloride, an antineoplastic agent used in combination with other antineoplastics in the treatment of leukemias. Indications and contraindications are mentioned. Adverse reactions to the drug are cited. Nursing implications and desired...

  • cytotoxic (Major drug group).  // Royal Society of Medicine: Medicines;2002, p181 

    This article provides information on cytotoxic drugs. These drugs are used mainly in the treatment of cancer. They have the essential property of preventing cell replication and inhibiting the growth of cancerous tumors. The most-used cytotoxics are the alkylating agents, which work by...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics